ArticleJournal of nanobiotechnology2025
Cinobufagin loaded Prussian blue-like nanoparticles for chemo/gas therapy of multidrug resistant cancer.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Folate-containing β-lactoglobulin/pectin nanocarriers for oxalipalladium delivery: physicochemical and in vitro evaluation in HCT116 cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Green synthesis of silver and zinc oxide nanoparticles for SERS-based detection of resonant fluorescent molecules.RSC advances · 2026Article
- Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives.Molecular cancer · 2026Review
- Article
- Cinobufagin as a Potential Intervention Against Liver Cancer-A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Nutraceuticals for Preventing and Managing Cancer Chemotherapy-Induced Cardiotoxicity: An Updated Comprehensive Review.Cardiology research and practice · 2026Review
- Clinical Translation of Functional Magnetic Nanoparticles for Intracellular Hyperthermia and Cancer Immunotherapy.International journal of nanomedicine · 2026Review
- Macrophage-derived long non-coding RNAs in cancer: pioneering targets for immune modulation and personalized therapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Tumor multidrug resistance (MDR) presents a major challenge to the efficacy of cancer chemotherapy. Pyroptosis, a form of regulated cell death distinct from apoptosis and unassociated with drug resistance, may restore tumor cells’ sensitivity to therapeutic drugs. Cinobufagin (CS-1) with efficient pyroptosis inducing capability showed the potential for the treatment of MDR cancer. However, the hydrophobic nature, low bioavailability, and possible toxic side effects under high dosage pose significant limitations on its clinical application. In this research endeavor, we have engineered a unique “chemo-gas” hybrid nanocomplexes (HA@Lip-CS-1@PBCO NPs) by wrapping CS-1 containing lipofilm onto manganese carbonyl hybrid Prussian blue nanoparticles (PBCO NPs) and modifying the targeting molecule HA on the surface. In vitro studies demonstrated that HA@Lip-CS-1@PBCO NPs, exhibiting high tumor-targeting capability, effectively induced pyroptosis in MCF-7/ADR cells through the Caspase-3/GSDME signaling pathway. In vivo assays indicated a strong inhibitory effect on MDR tumors with low CS-1 cardiotoxicity. In conclusion, this “chemo-gas” integrated therapy provides a new strategy for treating MDR tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.